Compare DXC & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DXC | ANIP |
|---|---|---|
| Founded | 1959 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.0B |
| IPO Year | N/A | N/A |
| Metric | DXC | ANIP |
|---|---|---|
| Price | $15.20 | $81.84 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 6 |
| Target Price | $15.33 | ★ $107.33 |
| AVG Volume (30 Days) | ★ 2.2M | 548.1K |
| Earning Date | 01-29-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.32 | 1.67 |
| Revenue | ★ $12,683,000,000.00 | $826,880,000.00 |
| Revenue This Year | N/A | $44.35 |
| Revenue Next Year | N/A | $11.13 |
| P/E Ratio | ★ $6.11 | $48.66 |
| Revenue Growth | N/A | ★ 48.87 |
| 52 Week Low | $11.82 | $54.10 |
| 52 Week High | $23.75 | $99.50 |
| Indicator | DXC | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 49.62 | 49.82 |
| Support Level | $13.41 | $78.79 |
| Resistance Level | $15.50 | $83.80 |
| Average True Range (ATR) | 0.76 | 2.63 |
| MACD | -0.07 | -0.11 |
| Stochastic Oscillator | 67.70 | 41.54 |
DXC Technology Co is a vendor-independent IT services provider. The company's operating segment includes Global Business Services (GBS) and Global Infrastructure Services (GIS). It generates maximum revenue from the GIS segment. GIS offerings include Cloud and Security; IT Outsourcing and Modern Workplace. Geographically, it derives a majority of revenue from the Other Europe region.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.